Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia

References

• Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 995–1005
   PubMed Web of Science ®Google Scholar
• Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, Raju I. Contribution of cystine-glutamate antiporters to the psychotomimetic affects of phencyclidine. Neuropsychopharmacology 2007; 33: 1760–1772
   PubMedGoogle Scholar
• Basan A, Kissling W, Leucht S. Valproate as an adjunct to antipsychotics for schizophrenia: A systematic review of randomized trials. Schizophr Res 2004; 70: 33–37
   PubMed Web of Science ®Google Scholar
• Farber NB. The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 2003; 1003: 119–130
   PubMed Web of Science ®Google Scholar
• Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog Brain Res 1998; 116: 421–437
   PubMed Web of Science ®Google Scholar
• Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 2002; 59: 521–529
   PubMed Web of Science ®Google Scholar
• Kao SJ, Wang D, Lin IH, Che IH. N-Acetylcysteine abrogates acute lung injury induced by endotoxin. Clin Exp Pharmacol Physiol 2006; 33: 33–40
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Pillai A, Joshi S, Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 2006; 2: 119–131
   Google Scholar
• Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109–142
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). 2002. Technology appraisal Guidance No. 43, Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London
   Google Scholar
• Olbrich HM, Valerius G, Rüsch N, Büchert M, Thiel T, Hennig J, et al. Frontolimbic glutamate alterations in first episode schizophrenia: Evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 2007; 9: 59–63
   Google Scholar
• Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998–1007
   PubMed Web of Science ®Google Scholar
• Perez-Neri I, Ramirez-Bermudez J, Montes S, Rios C. Possible mechanisms of neurodegeneration in schizophrenia. Neurochem Res 2006; 31: 1279–1294
   PubMed Web of Science ®Google Scholar
• Savas HA, Herken H, Yurekli M, Uz E, Tutkun H, Zoroglu SS, et al. Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 2002; 45: 57–61
   PubMed Web of Science ®Google Scholar
• Savas HA, Gergerlioglu HS, Armutcu F, Herken H, Yilmaz HR, Kocoglu E, et al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: Impact of past episodes. World J Biol Psychiatry 2006; 7: 51–55
   PubMed Web of Science ®Google Scholar
• Schulz SC, Thompson PA, Jacobs M, Ninan PT, Robinson D, Weiden PJ, et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 1999; 60: 366–372
   PubMed Web of Science ®Google Scholar
• Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord 2007; 107: 89–94
   PubMedGoogle Scholar
• Tebartz van Elst L, Valerius G, Büchert M, et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia. Evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005; 58: 724–730
   PubMed Web of Science ®Google Scholar
• Yanik M, Vural H, Tutkun H, Zoroglu SS, Savas HA, Herken H, et al. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 2004; 254: 43–47
   PubMed Web of Science ®Google Scholar
• Zoroglu SS, Herken H, Yurekli M, Uz E, Tutkun H, Savas HA, et al. The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatr Res 2002; 36: 309–315
   PubMed Web of Science ®Google Scholar